Biofilm infections between Scylla and Charybdis: interplay of host antimicrobial peptides and antibiotics

References

• Grants.nih.gov [homepage on the Internet]. Grants and fundings. Bethesda, MD: National Institutes of Health (NIH) [updated September 25, 2015; cited October 15, 2017]. Available from: https://grants.nih.gov/grants/guide/pa-files/PA-03-047.html. Accessed January 3, 2018.
   Google Scholar
• Pinto-Santini D, Salama NR. The biology of Helicobacter pylori infection, a major risk factor for gastric adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2005;14(8):1853–1858.
   PubMed Web of Science ®Google Scholar
• Collins D, Hogan AM, Winter DC. Microbial and viral pathogens in colorectal cancer. Lancet Oncol. 2011;12(5):504–512.
   PubMed Web of Science ®Google Scholar
• Johnson CH, Dejea CM, Edler D, et al. Metabolism links bacterial biofilms and colon carcinogenesis. Cell Metab. 2015;21(6):891–897.
   PubMed Web of Science ®Google Scholar
• Fong IW. New perspectives of infections in cardiovascular disease. Curr Cardiol Rev. 2009;5(2):87–104.
   PubMedGoogle Scholar
• Lanter BB, Sauer K, Davies DG. Bacteria present in carotid arterial plaques are found as biofilm deposits which may contribute to enhanced risk of plaque rupture. mBio. 2014;5(3):e01206–e01214.
   PubMed Web of Science ®Google Scholar
• Aslam S. Effect of antibacterials on biofilms. Am J Infect Control. 2008;36(10):S175.e9–S175.e11.
   PubMedGoogle Scholar
• Bryers JD. Medical biofilms. Biotechnol Bioeng. 2008;100(1):1–18.
   PubMed Web of Science ®Google Scholar
• Leid JG. Bacterial biofilms resist key host defenses. Microbe. 2009;4(2):66–70.
   Google Scholar
• López D, Vlamakis H, Kolter R. Biofilms. Cold Spring Harb Perspect Biol. 2010;2(7):a000398.
   PubMed Web of Science ®Google Scholar
• Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents. 2010;35(4):322–332.
   PubMed Web of Science ®Google Scholar
• Dufour D, Leung V, Lévesque CM. Bacterial biofilm: structure, function, and antimicrobial resistance. Endod Topics. 2012;22(1):2–16.
   Google Scholar
• Römling U, Balsalobre C. Biofilm infections, their resilience to therapy and innovative treatment strategies. J Intern Med. 2012;272(6):541–561.
   PubMed Web of Science ®Google Scholar
• Gupta P, Sarkar S, Das B, Bhattacharjee S, Tribedi P. Biofilm, pathogenesis and prevention – a journey to break the wall: a review. Arch Microbiol. 2016;198(1):1–15.
   PubMed Web of Science ®Google Scholar
• Wu H, Moser C, Wang HZ, Høiby N, Song ZJ. Strategies for combating bacterial biofilm infections. Int J Oral Sci. 2015;7(1):1–7.
   PubMed Web of Science ®Google Scholar
• Di Luca M, Maccari G, Maisetta G, Batoni G. BaAMPs: the database of biofilm-active antimicrobial peptides. Biofouling. 2015;31(2):193–199.
   PubMed Web of Science ®Google Scholar
• Strempel N, Strehmel J, Overhage J. Potential application of antimicrobial peptides in the treatment of bacterial biofilm infections. Curr Pharm Des. 2015;21(1):67–84.
   PubMed Web of Science ®Google Scholar
• Batoni G, Maisetta G, Esin S. Antimicrobial peptides and their interaction with biofilms of medically relevant bacteria. Biochim Biophys Acta. 2016;1858(5):1044–1060.
   PubMed Web of Science ®Google Scholar
• Pletzer D, Coleman SR, Hancock RE. Anti-biofilm peptides as a new weapon in antimicrobial warfare. Curr Opin Microbiol. 2016;33:35–40.
   PubMed Web of Science ®Google Scholar
• Rahnamaeian M, Cytryńska M, Zdybicka-Barabas A, et al. Insect antimicrobial peptides show potentiating functional interactions against Gram-negative bacteria. Proc Biol Sci. 2015;282(1806):20150293.
   PubMed Web of Science ®Google Scholar
• Yu G, Baeder DY, Regoes RR, Rolff J. Combination effects of antimicrobial peptides. Antimicrob Agents Chemother. 2016;60(3):1717–1724.
   PubMed Web of Science ®Google Scholar
• Dosler S, Karaaslan E, Alev Gerceker A. Antibacterial and anti-biofilm activities of melittin and colistin, alone and in combination with antibiotics against Gram-negative bacteria. J Chemother. 2016;28(2):95–103.
   PubMed Web of Science ®Google Scholar
• Chernysh S, Gordya N, Suborova T. Insect antimicrobial peptide complexes prevent resistance development in bacteria. PLoS One. 2015;10(7):e0130788.
   PubMed Web of Science ®Google Scholar
• Gordya N, Yakovlev A, Kruglikova A, et al. Natural antimicrobial peptide complexes in the fighting of antibiotic resistant biofilms: Calliphora vicina medicinal maggots. PLoS One. 2017;12(3):e0173559.
   PubMed Web of Science ®Google Scholar
• Leber A. Synergism testing: broth microdilution checkerboard and broth macrodilution methods. Clinical Microbiology Procedures Handbook. 4th ed. Washington, DC: ASM Press; 2016:5.16.1–5.16.23.
   Google Scholar
• Lewis K. Persister cells and the paradox of chronic infections. Microbe. 2010;5(10):429–437.
   Google Scholar
• Ciofu O, Rojo-Molinero E, Macià MD, Oliver A. Antibiotic treatment of biofilm infections. APMIS. 2017;125(4):304–319.
   PubMed Web of Science ®Google Scholar
• Bulet P, Stöcklin R. Insect antimicrobial peptides: structures, properties and gene regulation. Protein Pept Lett. 2005;12(1):3–11.
   PubMed Web of Science ®Google Scholar
• Mylonakis E, Podsiadlowski L, Muhammed M, Vilcinskas A. Diversity, evolution and medical applications of insect antimicrobial peptides. Philos Trans R Soc Lond B Biol Sci. 2016;371(1695):20150290.
   PubMed Web of Science ®Google Scholar
• Mataraci E, Dosler S. In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillin-resistant Staphylococcus aureus biofilms. Antimicrob Agents Chemother. 2012;56(12):6366–6371.
   PubMed Web of Science ®Google Scholar
• Hwang IS, Hwang JS, Hwang JH, et al. Synergistic effect and antibiofilm activity between the antimicrobial peptide coprisin and conventional antibiotics against opportunistic bacteria. Curr Microbiol. 2013;66(1):56–60.
   PubMed Web of Science ®Google Scholar
• Reffuveille F, de la Fuente-Núñez C, Mansour S, Hancock RE. A broad-spectrum antibiofilm peptide enhances antibiotic action against bacterial biofilms. Antimicrob Agents Chemother. 2014;58(9):5363–5371.
   PubMed Web of Science ®Google Scholar
• Kim KP, Kim YG, Choi CH, et al. In situ monitoring of antibiotic susceptibility of bacterial biofilms in a microfluidic device. Lab Chip. 2010;10(23):3296–3299.
   PubMed Web of Science ®Google Scholar
• Chernysh SI, Gordja NA. The immune system of maggots of the blow fly (Calliphora vicina) as a source of medicinal drugs. J Evol Biochem Physiol. 2011;47(6):524–533.
   Web of Science ®Google Scholar
• Ikawa K, Nakashima A, Morikawa N, et al. Clinical pharmacokinetics of meropenem and biapenem in bile and dosing considerations for biliary tract infections based on site-specific pharmacodynamic target attainment. Antimicrob Agents Chemother. 2011;55(12):5609–5615.
   PubMed Web of Science ®Google Scholar
• Pacifici GM. Clinical pharmacology of ampicillin in neonates and infants: effects and pharmacokinetics. Int J Pediatr. 2017;5(12):6383–6410.
   Google Scholar
• Patel KB, Nicolau DP, Nightingale CH, Quintiliani R. Pharmacokinetics of cefotaxime in healthy volunteers and patients. Diagn Microbial Infect Dis. 1995;22(1–2):49–55.
   PubMed Web of Science ®Google Scholar
• Nesseler N, Verdier MC, Launey Y, et al. High-dose continuous oxacillin infusion results in achievement of pharmacokinetics targets in critically ill patients with deep sternal wound infections following cardiac surgery. Antimicrob Agents Chemother. 2014;58(9):5448–5455.
   PubMed Web of Science ®Google Scholar
• James JK, Palmer SM, Levine DP, Rybak MJ. Comparison of conventional dosing versus continuous-infusion vancomycin therapy for patients with suspected or documented gram-positive infections. Antimicrob Agents Chemother. 1996;40(3):696–700.
   PubMed Web of Science ®Google Scholar
• Burdet C, Pajot O, Couffignal C, et al. Population pharmacokinetics of single-dose amikacin in critically ill patients with suspected ventilator-associated pneumonia. Eur J Clin Pharmacol. 2015;71(1):75–83.
   PubMed Web of Science ®Google Scholar
• Aung TY, Thwin MH, Zin T, Nwe Oo K, Aye NN, Sin S. Comparative pharmacokinetics of kanamycin between multi-drug resistant tuberculosis patients and healthy volunteers. Int J Med Pharm. 2014;2(2):45–59.
   Google Scholar
• Medellín-Garibay SE, Rueda-Naharro A, Peña-Cabia S, García B, Romano-Moreno S, Barcia E. Population pharmacokinetics of gentamicin and dosing optimization for infants. Antimicrob Agents Chemother. 2015;59(1):59482–59489.
   Web of Science ®Google Scholar
• Josefsson K, Bergan T, Magni L. Dose-related pharmacokinetics after oral administration of a new formulation of erythromycin base. Br J Clin Pharmacol. 1982;13(5):685–691.
   PubMed Web of Science ®Google Scholar
• Lipman J, Scribante J, Gous AG, Hon H, Tshukutsoane S. Pharmacokinetic profiles of high-dose intravenous ciprofloxacin in severe sepsis. Antimicrob Agents Chemother. 1998;42(9):2235–2239.
   PubMed Web of Science ®Google Scholar
• Agwuh KN, MacGowan A. Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother. 2006;58(2):256–265.
   PubMed Web of Science ®Google Scholar
• Ambrose PJ. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. Clin Pharmacokinet. 1984;9(3):222–238.
   PubMed Web of Science ®Google Scholar
• National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests. Approved standard M2-A8. Wayne, PA: NCCLS; 2003.
   Google Scholar
• Clinical Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 10th edition, M07-A10. Wayne, PA: CLSI; 2015.
   Google Scholar